Home

Anti-estrogen Use, Estrogen Receptor Expression, Smoking Patterns, and Survival of Women with Non-Small-Cell Lung Cancer: A Manitoba Perspective

Show simple item record

dc.contributor.supervisor Dr. Gary Harding (CancerCare Manitoba) and Dr. Marshall Pitz (CancerCare Manitoba). en_US
dc.contributor.author Lother, Sylvain
dc.date.accessioned 2012-03-12T19:14:35Z
dc.date.available 2012-03-12T19:14:35Z
dc.date.issued 2012-03-12
dc.identifier.uri http://hdl.handle.net/1993/5175
dc.description.abstract Lung cancer is the leading cause of cancer death worldwide. Gender differences in lung cancer outcomes are known. When compared to men, women have significantly better survival and women are more likely to develop lung cancer when nonsmokers. Research suggests estrogen plays a key role in the risk of development and outcomes of lung cancer. Accordingly, anti-estrogen use should also influence survival in female non-small cell lung cancer (NSCLC) patients. In this study we compared mortality among anti-estrogen users and non-users. METHODS: This population-based study had a retrospective study design. Using the Manitoba Cancer Registry (MCR) we identified all women diagnosed with NSCLC from 2000-2007. The Drug Program Information Network (DPIN) was accessed to establish patients that received anti-estrogens. Demographic data (e.g. smoking patterns, stage, histology) was gathered by chart review. Mortality rates for anti-estrogen users and non-users were compared using Kaplan-Meier survival functions and Cox regression models. RESULTS: 2320 women fit our patient criteria, of which 156 had received prior anti-estrogens. A positive smoking history was documented in 88%, 62% being former vs. 26% current smokers. A history of 30+ packyears was seen in 55%. Exposure to anti-estrogen was associated with a significantly decreased mortality (HR 0.718, p = 0.0031). Overall survival with anti-estrogen vs. none resulted in median survival of 1.89 vs. 0.93 years, respectively (p < 0.0001). CONCLUSIONS: Our results demonstrate that anti-estrogens are associated with decreased mortality from NSCLC. These findings supplement and reinforce past evidence that estrogen plays a key factor in the biology and outcomes of NSCLC. en_US
dc.rights info:eu-repo/semantics/openAccess
dc.subject medicine en_US
dc.title Anti-estrogen Use, Estrogen Receptor Expression, Smoking Patterns, and Survival of Women with Non-Small-Cell Lung Cancer: A Manitoba Perspective en_US
dc.type info:eu-repo/semantics/bachelorThesis
dc.type bachelor thesis en_US
dc.degree.discipline Medicine en_US
dc.contributor.examiningcommittee Medicine en_US
dc.degree.level Bachelor of Science (B.Sc.) en_US
dc.description.note October 2011 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics